» Articles » PMID: 36482765

Aggressive and Drug-resistant Pancreatic Cancer: Challenges and Novel Treatment Approaches

Overview
Journal Discov Med
Specialty General Medicine
Date 2022 Dec 9
PMID 36482765
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic cancer, especially pancreatic ductal adenocarcinoma (PDAC), has a mortality rate that is among the highest. The single therapy option that has the potential to be curative for the illness is surgery, which is generally accepted as being the only effective treatment available. This is because most pancreatic tumors are intractable to chemotherapy. Because of the severe nature of the illness that these tumors cause, only around twenty percent of these tumors can be surgically removed when the first symptoms appear. This is due to the harm that these tumors cause. Since surgery in late-stage cases does not usually offer benefits, here we shed light on the molecular mechanisms of the most aggressive pancreatic tumors that are highly resistant to drugs. We also describe two latest novel treatment approaches that are used to combat this fierce tumor: targeting exosome-mediated tumor-enhancement mechanisms and radiation therapy in combination with adverse effect-mitigating agents. Effective treatments for pancreatic cancer are needed to meet this urgent medical need.

Citing Articles

Temporary uterine artery blocking and uterine artery embolization in treating cesarean scar pregnancy.

Zeng K, Lei X, Xia T Wideochir Inne Tech Maloinwazyjne. 2025; 19(3):377-383.

PMID: 40041110 PMC: 11867203. DOI: 10.20452/wiitm.2024.17890.


Targeting the autophagy-miRNA axis in prostate cancer: toward novel diagnostic and therapeutic strategies.

Syed R, Alshammari M, Banu H, Khojali W, Jafar M, Nagaraju P Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(10):7421-7437.

PMID: 38761210 DOI: 10.1007/s00210-024-03153-0.


Role of long non-coding RNA ELFN1-AS1 in carcinogenesis.

HajiEsmailPoor Z, Fayazi A, Teymouri M, Tabnak P Discov Oncol. 2024; 15(1):74.

PMID: 38478184 PMC: 10937879. DOI: 10.1007/s12672-024-00929-x.


CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.

Liu K, Li L, Han G Front Endocrinol (Lausanne). 2024; 14:1226547.

PMID: 38333724 PMC: 10850383. DOI: 10.3389/fendo.2023.1226547.


Nuclear overexpression of DNA damage-inducible transcript 4 (DDIT4) is associated with aggressive tumor behavior in patients with pancreatic tumors.

Tajik F, Fattahi F, Rezagholizadeh F, Bouzari B, Babaheidarian P, Baghai Wadji M Sci Rep. 2023; 13(1):19403.

PMID: 37938616 PMC: 10632485. DOI: 10.1038/s41598-023-46484-3.